Administering licensed vaccines is a safe and inexpensive way to prevent disability and death caused by infectious diseases. However, every year children and adults all over the world continue to suffer from diseases for which there are no effective vaccines. At the CIR, we believe that developing new vaccines is necessary to save lives.
The CIR’s study teams are dedicated to the safe and ethical conduct of phase I and II clinical vaccine trials in three main categories: pediatric studies, flavivirus plus studies and mucosal and vaccine challenge (MVAC) studies. Each team is comprised of Johns Hopkins Bloomberg School of Public Health faculty, research nurses, study coordinators and research assistants who are devoted to the CIR’s mission. Collectively, we have conducted clinical vaccine trials for COVID-19, HPV, respiratory syncytial virus [RSV], human metapneumovirus [HMPV], influenza, and parainfluenza [PIV], flavivirus vaccines (dengue virus, West Nile virus and Zika), ebola, enteric vaccines (norovirus, enterotoxigenic E. coli (ETEC), Shigella and many other diseases and viruses.
The CIR partners with many sponsors, including the National Institutes of Health, Department of Defense, and private industry companies to evaluate new investigational vaccines. We conduct both outpatient and inpatient clinical trials at our facilities located on the JHU East Baltimore Campus, Johns Hopkins Bayview Campus as well as off-site at private practices in Laurel, Dundalk, Columbia and White Marsh.